---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002799"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:46:23.617507+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics: 2025 preliminary revenue ~$823M, Sephience $112M; 2026 guidance $700-800M product revenue

## Summary
- Preliminary 2025 total product & royalty revenue ~$823.4M, exceeding prior guidance; product revenue ~$587.8M.
- Sephience (sepiapterin) net revenue $112.1M since launch, Q4 alone $92.5M; 946 patients on commercial therapy as of Dec 31.
- Closed sale of remaining Evrysdi royalty to Royalty Pharma for $240M upfront plus up to $60M milestones; retains $150M milestone.
- 2026 guidance: product revenue $700-800M (19-36% YoY growth); GAAP R&D/SG&A $775-815M, non-GAAP $680-720M.
- End-of-Phase 2 meeting for votoplam HD program; Phase 3 trial to start H1 2026; FDA open to Accelerated Approval.

## SEC filing metadata
- accession: 0001104659-26-002799
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465926002799/0001104659-26-002799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465926002799/tmb-20260112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002799
- JSON: https://secwatch.observer/filing/0001104659-26-002799.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.